+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Schizoaffective Disorder - Pipeline Insight, 2021

  • ID: 5237656
  • Drug Pipelines
  • January 2021
  • Region: Global
  • 60 pages
  • DelveInsight

FEATURED COMPANIES

  • Gedeon Richter
  • Lyndra Therapeutics
  • Reviva Biopharmaceuticals
  • Roche
This “Schizoaffective disorder - Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Schizoaffective disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Schizoaffective disorder Understanding

Schizoaffective disorder: Overview

Schizoaffective disorder is a chronic mental health condition that involves symptoms of both schizophrenia and a mood disorder like major depressive disorder or bipolar disorder. The two types of schizoaffective disorder are bipolar type and depressive type. The bipolar type includes both dramatic "highs," called manic episodes, and "lows," called depressive episodes. The depressive type includes only depressive episodes. The Depressive episodes are marked by low energy and activity, a feeling of hopelessness, and an inability to perform everyday tasks. Genetic and environmental factors can increase the risk of getting a mental illness.

Symptoms

The symptoms of Schizoaffective disorder include:
  • Delusions
  • Hallucinations
  • Impaired communication and speech
  • Bizarre or unusual behavior
  • Symptoms of depression
  • Periods of manic mood
  • Impaired occupational, academic and social functioning
  • Problems with managing personal care
Diagnosis

A diagnosis of Schizoaffective disorder is based upon a thorough psychiatric evaluation, a detailed patient history, and a variety of specialized tests. Tests may first be performed to rule out other mental health disorders and concluding that symptoms are not due to substance use, medication or a medical condition. Other imaging test like an MRI or CT scan may be done for detailed analysis.

Treatment

Treatment for Schizoaffective disorder includes a combination of medications, psychotherapy and life skills training. Treatment varies, depending on the type and severity of symptoms and whether the disorder is the depressive or bipolar type. Medication aims to relieve psychotic symptoms, stabilize mood and treat depression such as antipsychotics, mood-stabilizing medications, and antidepressants. In addition to medication, psychotherapy may help. For adults who do not respond to psychotherapy or medications, electroconvulsive therapy (ECT) may be considered.

Schizoaffective disorder Emerging Drugs Chapters

This segment of the Schizoaffective disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Schizoaffective disorder Emerging Drugs

Risperidone: Lyndra Therapeutics

Risperidone (LYN-005) is an oral, extended release formulation, presented in a capsule dosage form with an aim of reducing the frequency of dosing orally-administered medications to once weekly or less. It is a dopamine D2 receptor antagonists and is currently under Phase II development for the treatment of Schizoaffective disorder.

Brilaroxazine: Reviva Biopharmaceuticals

Brilaroxazine is a dopamine-serotonin system stabilizer. The molecule is a potent partial agonist at the dopamine D2, D3, and D4 receptors and the serotonin 5-HT1A and 5-HT2A receptors, as well as an antagonist at the serotonin 5-HT6 and 5-HT7 receptors. Reviva Biopharmaceuticals has completed phase 2 clinical study for brilaroxazine in patients with schizophrenia and schizoaffective disorders where it demonstrated robust efficacy with remission in acute schizophrenia and promising efficacy for comorbid negative, cognition, depression and mood symptoms.

Schizoaffective disorder: Therapeutic Assessment

This segment of the report provides insights about the different Schizoaffective disorder drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Schizoaffective disorder

There are approx. 8+ key companies which are developing the therapies for Schizoaffective disorder. The companies which have their Schizoaffective disorder drug candidates in the most advanced stage, i. e. phase II include, Reviva Biopharmaceuticals.

Phases

This report covers around 8+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Schizoaffective disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Schizoaffective disorder: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Schizoaffective disorder therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Schizoaffective disorder drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Schizoaffective disorder R&D. The therapies under development are focused on novel approaches to treat/improve Schizoaffective disorder.
Schizoaffective disorder Report Insights
  • Schizoaffective disorder Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Schizoaffective disorder Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Schizoaffective disorder drugs?
  • How many Schizoaffective disorder drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Schizoaffective disorder?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Schizoaffective disorder therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Schizoaffective disorder and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Reviva Biopharmaceuticals
  • Lyndra Therapeutics
  • Roche
  • Gedeon Richter
Key Products
  • Brilaroxazine
  • Risperidone
  • Ralmitaront
  • Cariprazine

This report will be delivered within 1-3 business days
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Gedeon Richter
  • Lyndra Therapeutics
  • Reviva Biopharmaceuticals
  • Roche
Introduction

Executive Summary

Schizoaffective disorder: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Schizoaffective disorder - Analytical Perspective

In-depth Commercial Assessment
  • Schizoaffective disorder companies’ collaborations, Licensing, Acquisition - Deal Value Trends
Schizoaffective disorder Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
  • Comparative Analysis
Risperidone: Lyndra Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
Cariprazine - Gedeon Richter
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Schizoaffective disorder Key Companies

Schizoaffective disorder Key Products

Schizoaffective disorder- Unmet Needs

Schizoaffective disorder- Market Drivers and Barriers

Schizoaffective disorder- Future Perspectives and Conclusion

Schizoaffective disorder Analyst Views

Schizoaffective disorder Key Companies

Appendix

List of Tables
Table 1 Total Products for Schizoaffective disorder
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Schizoaffective disorder
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
  • Reviva Biopharmaceuticals
  • Lyndra Therapeutics
  • Roche
  • Gedeon Richter
Note: Product cover images may vary from those shown
Adroll
adroll